Making Visible HTLV Infection in a Non-endemic Area of Argentina.
HTLV follow-up
HTLV outpatient unit
HTLV-1/2 infection
neglected disease
non-endemic area
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
03
2022
accepted:
27
05
2022
entrez:
26
7
2022
pubmed:
27
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
In Argentina, the human T-cell lymphotropic virus type 1 (HTLV-1) infection has been documented mainly among blood banks with a prevalence of ~0.02-0.046% for Buenos Aires city, 0.8% for the northeast, and 1% for the northwest; both areas are considered endemic for HTLV-2 and 1, respectively. Policies and specific guidelines for testing blood donors for HTLV are included since 2005. Screening for antibodies is performed at blood banks and confirmatory testing is performed at reference laboratories. There are no specific recommendations for the assistance of communities and individuals affected, nor referral to specialized clinics on the HTLV infection. In 2016, as a strategy of intervention, we opened a specialized clinical attendance in a referral infectious diseases public hospital for the comprehensive approach to patients with HTLV, offering follow-up and counseling for patients and their families for the early diagnosis of HTLV-1/2 and related diseases. During the study, 124 patients with presumptive HTLV positive diagnosis from blood bank, symptomatic patients (SPs), relatives, and descendants visited the unit. A total of 46 patients were HTLV positive (38 HTLV-1 and 8 HTLV-2). There were nine SPs (2 adult T-cell leukemia/lymphoma [ATL] and 7 HTLV-1-associated myelopathy/tropical spastic paraparesis [HAM/TSP]). All patients with HTLV-1 and-2 were offered to study their relatives. Two out of 37 (5.4%) descendants tested were positive for HTLV-1. Sexual partners were studied; among 6 out of 11 couples (54.5%) were found positive (5 HTLV-1 and 1 HTLV-2). Other relatives, such as mothers (1/2) and siblings (1/6), were positive for HTLV-1. According to the place of birth among HTLV-1 carriers, 58% were born in an endemic area or in countries where HTLV infection is considered endemic while for HTLV-2 carriers, 12.5% were born in an endemic area of Argentina. The proviral load (pVL) was measured in all, patients with HTLV-1 being higher in symptomatic compared with asymptomatic carriers. In addition, two pregnant women were early diagnosed during their puerperium and breastmilk replacement by formula was indicated. Inhibition of lactation was also indicated. Our study provides tools for a multidisciplinary approach to the infection and reinforces the importance of having specialized clinical units in neglected diseases, such as HTLV for counseling, clinical and laboratory follow-up, and providing useful information for patients for self-care and that of their families.
Identifiants
pubmed: 35879924
doi: 10.3389/fmed.2022.892159
pmc: PMC9307993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
892159Informations de copyright
Copyright © 2022 Simioli, Bouzas, Mijalovsky, Pineda, Mammana, Mangano and Orduna.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Viruses. 2017 Dec 21;10(1):
pubmed: 29267225
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
Leukemia. 1995 Dec;9(12):2087-92
pubmed: 8609721
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
J Immigr Minor Health. 2009 Apr;11(2):99-104
pubmed: 18175218
PLoS One. 2019 Nov 22;14(11):e0225596
pubmed: 31756234
AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):407-17
pubmed: 10195750
AIDS Res Hum Retroviruses. 1994 Nov;10(11):1567-71
pubmed: 7888211
Blood. 1992 Sep 15;80(6):1537-45
pubmed: 1520878
Blood. 2010 Aug 26;116(8):1211-9
pubmed: 20448111
J Med Virol. 2007 Dec;79(12):1974-8
pubmed: 17935192
Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5
pubmed: 6979048
J Acquir Immune Defic Syndr (1988). 1992 Dec;5(12):1275-6
pubmed: 1453338
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):193-201
pubmed: 8680892
Medicina (B Aires). 1998;58(4):411-4
pubmed: 9816704
J Acquir Immune Defic Syndr (1988). 1990;3(11):1096-101
pubmed: 2213510
Front Med (Lausanne). 2021 Nov 10;8:758352
pubmed: 34901072
Int J Cancer. 1984 Jun 15;33(6):745-9
pubmed: 6329966
Ann Neurol. 2004 Jul;56(1):10-9
pubmed: 15236397
J Pediatric Infect Dis Soc. 2014 Sep;3 Suppl 1:S24-9
pubmed: 25232474
Am J Trop Med Hyg. 1999 Apr;60(4):623-9
pubmed: 10348238
Eur J Epidemiol. 1996 Feb;12(1):27-31
pubmed: 8817174
Leuk Lymphoma. 2000 Mar;37(1-2):225-7
pubmed: 10721791
AIDS Res Hum Retroviruses. 2017 Nov;33(11):1126-1133
pubmed: 28540757
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
Pathol Int. 2002 May-Jun;52(5-6):348-57
pubmed: 12100517
Virology. 1993 Dec;197(2):576-84
pubmed: 8249280
Vox Sang. 2002 Nov;83(4):364-5
pubmed: 12437526
J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):301-8
pubmed: 15076246
J Acquir Immune Defic Syndr (1988). 1990;3(7):741-2
pubmed: 2352127
PLoS Negl Trop Dis. 2018 Jun 1;12(6):e0006550
pubmed: 29856738
AIDS Res Hum Retroviruses. 2005 Jan;21(1):1-4
pubmed: 15665638
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(4):152-66
pubmed: 21558754
Cancer Sci. 2012 Oct;103(10):1857-60
pubmed: 22738276
Princess Takamatsu Symp. 1984;15:129-35
pubmed: 6152757
J Med Virol. 2007 Dec;79(12):1914-20
pubmed: 17935172
Jpn J Cancer Res. 1992 Mar;83(3):236-9
pubmed: 1582883
J Viral Hepat. 2015 Jan;22 Suppl 1:26-45
pubmed: 25560840
Lancet. 1989 Feb 25;1(8635):441
pubmed: 2563817